<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2019-8-1-29-36</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-645</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL TECHNOLOGY</subject></subj-group></article-categories><title-group><article-title>ЛАБОРАТОРНОЕ ОБОРУДОВАНИЕ НА ЭТАПЕ ФАРМАЦЕВТИЧЕСКОЙ РАЗРАБОТКИ МЯГКИХ ЛЕКАРСТВЕННЫХ СРЕДСТВ</article-title><trans-title-group xml:lang="en"><trans-title>LABORATORY EQUIPMENT DURING PHARMACEUTICAL DEVELOPMENT OF SEMI-SOLID PREPARATIONS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ляпунов</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyapunov</surname><given-names>N. A.</given-names></name></name-alternatives><email xlink:type="simple">lyapunov.na@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Безуглая</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Bezuglaya</surname><given-names>E. P.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ляпунов</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyapunov</surname><given-names>A. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зинченко</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zinchenko</surname><given-names>I. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брылёва</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Bryleva</surname><given-names>K. Yu.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лысокобылка</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lysokobilka</surname><given-names>A. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГНУ «НТК «Институт монокристаллов» НАН Украины</institution><country>Украина</country></aff><aff xml:lang="en"><institution>State Scientific Institution «Institute for Single Crystals» of the National Academy of Sciences of Ukraine</institution><country>Ukraine</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>14</day><month>02</month><year>2019</year></pub-date><volume>8</volume><issue>1</issue><fpage>29</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ляпунов Н.А., Безуглая Е.П., Ляпунов А.Н., Зинченко И.А., Брылёва Е.Ю., Лысокобылка А.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Ляпунов Н.А., Безуглая Е.П., Ляпунов А.Н., Зинченко И.А., Брылёва Е.Ю., Лысокобылка А.А.</copyright-holder><copyright-holder xml:lang="en">Lyapunov N.A., Bezuglaya E.P., Lyapunov A.N., Zinchenko I.A., Bryleva K.Y., Lysokobilka A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/645">https://www.pharmjournal.ru/jour/article/view/645</self-uri><abstract><sec><title>Введение</title><p>Введение. При разработке лекарственных препаратов необходимо использовать лабораторное оборудование, моделирующее опытнопромышленное и промышленное оборудование. Для производства мягких лекарственных средств (МЛС) ключевыми видами оборудования являются диспергаторы «ротор-статор» и вакуумные реакторы-гомогенизаторы.</p></sec><sec><title>Цель</title><p>Цель. Исследование функциональных характеристик лабораторного оборудования: диспергатора Megatron® MT 1-50 SHS F/2 («Kinematica AG», Швейцария) и вакуумного реактора-гомогенизатора РП-5 («Промвит», Украина).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. При разработке препарата-генерика Пенцикловир крем 1% методами оптической микроскопии и лазерной дифракции изучен размер частиц в суспензии пенцикловира исходно и после диспергирования. В креме, изготовленном в реакторе, методом оптической микроскопии определён размер частиц дисперсной фазы эмульсии м/в и суспензии, а также отсутствие пузырьков воздуха. Методом жидкостной хроматографии в 9 пробах крема, отобранных из реактора, определено содержание пенцикловира. Методом ротационной вискозиметрии исследованы реологические свойства крема. Методом атомно-эмиссионной спектрометрии с индуктивно связанной плазмой изучено выделение примесей металлов в суспензию и крем из оборудования.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. С увеличением частоты вращения ротора размер частиц пенцикловира в суспензии уменьшается. Диспергатор эффективно выполняет своё функциональное назначение при частоте вращения ротора 25000 об/мин. В креме, изготовленном в реакторе, отклонения в количественном содержании пенцикловира от среднего значения в каждой пробе находятся в рамках неопределённости аналитической методики, что свидетельствует о его однородном распределении. Реактор обеспечивает эффективное диспергирование и однородное распределение масляной фазы, предотвращает образование газовой эмульсии и позволяет получить крем, который по реологическим свойствам соответствует референтному препарату Фенистил® Пенцивир крем 1%. В процессе производства в суспензию и крем не выделяются примеси металлов из оборудования.</p></sec><sec><title>Заключение</title><p> Заключение. Диспергатор и реактор при производстве крема с пенцикловиром эффективно выполняют своё функциональное назначение. На участках производства МЛС рационально совмещать эти два вида оборудования. Диспергатор также пригоден для изготовления эмульсий с очень маленьким размером частиц дисперсной фазы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. When developing drugs it is necessary to use laboratory equipment that simulates pilot and industrial equipment. For the production of semi-solid preparations the key equipment are rotor-stator dispersers and vacuum reactors-homogenizers.</p></sec><sec><title>Aim</title><p>Aim. Investigation of the functional characteristics of laboratory equipment: Megatron® MT 1-50 dispersant SHS F/2 (Kinematica AG, Switzerland) and the RP-5 vacuum homogenizer reactor (Promvit, Ukraine).</p></sec><sec><title>Materials and methods</title><p>Materials and methods. During development a generic product Penciclovir cream 1% the initial particle size in suspension of penciclovir and particle size after grinding were studied by optical microscopy and laser diffraction methods. In a cream made in the reactor, the particle size of the dispersed phase of the o/w emulsion and suspension, as well as the absence of air bubbles, were determined by optical microscopy. The assay of penciclovir in 9 samples of the cream taken from the reactor-homogenizer was performed by liquid chromatography. By the of rotational viscometry method the rheological properties of the cream were studied. By the inductively coupled plasma atomic emission spectroscopy the getting of metal impurities from the disperser and the reactor-homogenizer into the suspension and cream were investigated.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. With an increase in the rotor speed, the particle size of penciclovir in suspension decreases. The disperser effectively performs its function at a rotor speed of 25,000 rpm. In a cream made in the reactor, the deviations in the quantitative content of penciclovir from the average value in each sample are within the uncertainty of the analytical procedure, which indicates its uniform distribution. The reactor provides effective dispersion and uniform distribution of the oil phase, prevents the formation of a gas emulsion and allows getting a cream that, according to its rheological properties, corresponds to the reference preparation Fenistil® Pencivir cream 1%. In the production process metal impurities were not emitted into the suspension and the cream from the equipment.</p></sec><sec><title>Conclusion</title><p>Conclusion. The disperser and the reactor during the production of cream with penciclovir are suitable for their intended use. It is rational to combine these two types of equipment at the sites for the production of semi-solid preparations. The disperser can also be used to produce emulsions with a very small particle size of the dispersed phase.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>пенцикловир</kwd><kwd>суспензия</kwd><kwd>эмульсия</kwd><kwd>крем</kwd><kwd>диспергатор</kwd><kwd>реактор-гомогенизатор</kwd><kwd>размер частиц</kwd><kwd>однородность</kwd><kwd>примеси элементов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>penciclovir</kwd><kwd>suspension</kwd><kwd>emulsion</kwd><kwd>cream</kwd><kwd>disperser</kwd><kwd>reactor-homogenizer</kwd><kwd>particle size</kwd><kwd>uniformity</kwd><kwd>elemental impurities</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Компендиум 2016 – лекарственные препараты / Под ред. В.Н. Коваленко. К.: МОРИОН. 2016; 2416 с.</mixed-citation><mixed-citation xml:lang="en">Compendium 2016 – drugs / Ed. V.N. Kovalenko. K.: MORION. 2016: 2416 s. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ляпунова А. М., Безугла О. П., Лібіна В. В., Андріанова Т. В. Дослідження м’яких лікарських засобів з мометазону фуроатом на емульсійних основах. Український біофармацевтичний журнал. 2017; 53(6): 9–18.</mixed-citation><mixed-citation xml:lang="en">Lyapunova A. M., Bezugla O. P., Lіbіna V. V., Andrіanova T. V. Research of soft drugs with mometasone furoate on emulsion bases. Ukrainian biopharmaceutical magazine. 2017; 53(6): 9–18 (In Ukr.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ляпунов Н. А., Зинченко И. А., Безуглая Е. П. Оценка однородности распределения лекарственных и вспомогательных веществ в мягких лекарственных средствах. Фармаком. 2015; 2: 33–40.</mixed-citation><mixed-citation xml:lang="en">Lyapunov N. A., Zinchenko I. A., Bezuglaya E. P. Evaluation of the homogeneity of the distribution of drugs and auxiliaries in soft drugs. Farmakom. 2015; 2: 33–40 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Регистр лекарственных средств России. Available at: http://grls.rosminzdrav.ru (accessed 05.08.2018).</mixed-citation><mixed-citation xml:lang="en">Register of medicines of Russia. Available at: http://grls.rosminzdrav.ru (accessed 05.08.2018) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство для предприятий фармацевтической промышленности. Методические рекомендации. Ч. I. Руководство по валидации методик анализа лекарственных средств / Под ред. Н. В. Юргеля, А. Л. Младенцева, А. В. Бурдейна и др. М.: Изд-во «Спорт и культура – 2000». 2007; 5–92.</mixed-citation><mixed-citation xml:lang="en">Guide for enterprises of the pharmaceutical industry. Guidelines. Part I. Guidelines for the validation of methods for analyzing drugs / Ed. N. V. Yurgelya, A. L. Mladentseva, A. V. Burdeina i dr. M.: Publishing house «Sport and Culture – 2000». 2007; 5–92 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev 1 Guideline on process validation for finished products – information and data to be provided in regulatory submissions, 27 February 2014.</mixed-citation><mixed-citation xml:lang="en">EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev 1 Guideline on process validation for finished products – information and data to be provided in regulatory submissions, 27 February 2014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">EMA/CHMP/ICH/353369/2013 ICH guideline Q3D on elemental impurities, 25 July 2016.</mixed-citation><mixed-citation xml:lang="en">EMA/CHMP/ICH/353369/2013 ICH guideline Q3D on elemental impurities, 25 July 2016.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">EMA/CHMP/QWP/BWP/245074/2015 Guideline on manufacture of the finished dosage form, 4 July 2017.</mixed-citation><mixed-citation xml:lang="en">EMA/CHMP/QWP/BWP/245074/2015 Guideline on manufacture of the finished dosage form, 4 July 2017.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">EMA/INS/GMP/79766/2011 Quality Risk Management (ICH Q9), 31 January 2011.</mixed-citation><mixed-citation xml:lang="en">EMA/INS/GMP/79766/2011 Quality Risk Management (ICH Q9), 31 January 2011.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">EMA/INS/GMP/79818/2011 Pharmaceutical Quality System (ICH Q10), 31 January 2011.</mixed-citation><mixed-citation xml:lang="en">EMA/INS/GMP/79818/2011 Pharmaceutical Quality System (ICH Q10), 31 January 2011.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">EMEA/CHMP/167068/2004 – ICH. – Part I: Note for Guidance on Pharmaceutical Development (ICH Topic Q 8 (R2) Pharmaceutical Development). – Part II: Annex to Note for Guidance on Pharmaceutical Development (ICH Topic Q 8 Annex Pharmaceutical Development), June 2009.</mixed-citation><mixed-citation xml:lang="en">EMEA/CHMP/167068/2004 – ICH. – Part I: Note for Guidance on Pharmaceutical Development (ICH Topic Q 8 (R2) Pharmaceutical Development). – Part II: Annex to Note for Guidance on Pharmaceutical Development (ICH Topic Q 8 Annex Pharmaceutical Development), June 2009.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">European Pharmacopoeia. 9th Edition. European Directorate for the Quality of Medicines (EDQM). Council of Europe, 67075 Strasbourg Cedex, France 2016; 4016 p.</mixed-citation><mixed-citation xml:lang="en">European Pharmacopoeia. 9th Edition. European Directorate for the Quality of Medicines (EDQM). Council of Europe, 67075 Strasbourg Cedex, France 2016; 4016 p.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
